• In late June 2026, Bristol-Myers Squibb was removed from several Russell growth benchmarks and simultaneously added to the Russell 1000 Value Defensive and Russell 1000 Defensive Indexes, signalling a shift in how index providers classify the company.
• This reclassification could alter how many index-linked and style-focused funds hold Bristol-Myers Squibb, potentially changing its investor base and how it is compared with peers such as Merck, Pfizer, and Johnson & Johnson.
• We’ll now examine how Bristol-Myers Squibb’s move into value and defensive indexes may influence its existing investment narrative and risk profile.

Find 42 companies with promising cash flow potential yet trading below their fair value.

Bristol-Myers Squibb Investment Narrative Recap

To own Bristol Myers Squibb today, you need to believe it can offset looming patent cliffs and pricing pressure with its newer drugs and partnerships, while using its balance sheet and dividend to support returns. The shift into Russell value and defensive indexes mainly affects how some funds own the stock, rather than the underlying business. The more immediate swing factors still look like US pricing policy changes and how successfully new launches scale.

Among recent updates, the proposed expansion of the Medicare Drug Price Negotiation Program feels most relevant to this reclassification. Being tagged as a value and defensive name may focus attention even more on Bristol Myers Squibb’s exposure to US pricing reform, since policy changes could affect the very cash flows income and defensive investors often care about, while its pipeline, including Camzyos and cell therapies, remains central to offsetting future revenue erosion.

Yet behind Bristol Myers Squibb’s value label, investors should also be aware of growing policy scrutiny around drug pricing and intellectual property...

Bristol-Myers Squibb's narrative projects $40.1 billion revenue and $8.6 billion earnings by 2029. This requires revenue to decline by 6.2% per year and an earnings increase of $1.3 billion from $7.3 billion today.

Uncover how Bristol-Myers Squibb's forecasts yield a $62.96 fair value, a 8% upside to its current price.

Exploring Other Perspectives

While the consensus view is cautious, the most optimistic analysts expected revenue near US$43.5 billion and earnings of US$10.4 billion by 2029, so this defensive reclassification and policy risk could push those upbeat expectations to be revisited in very different ways.

Explore 8 other fair value estimates on Bristol-Myers Squibb - why the stock might be worth 18% less than the current price!

The Verdict Is Yours

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Bristol-Myers Squibb research is our analysis highlighting 3 key rewards and 3 important warning signs that could impact your investment decision.
• Our free Bristol-Myers Squibb research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Bristol-Myers Squibb's overall financial health at a glance.

Looking For Alternative Opportunities?

Opportunities like this don't last. These are today's most promising picks. Check them out now:

• We've uncovered the 7 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.
• The future of work is here. Discover the 29 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.
• Invest in the nuclear renaissance through our list of 89 elite nuclear energy infrastructure plays powering the global AI revolution.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.